Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance

By Pebody R.G.   Gay N.J.   Hesketh L.M.   Vyse A.   Morgan-Capner P.   Brown D.W.   Litton P.   Miller E.  

Vaccine, Vol. 20, Iss. 7, 2002-01 ,pp. : 1134-1140

Elsevier

Access to resources Recommend Favorite

Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age *

By Klinge  

Vaccine, Vol. 18, Iss. 27, 2000-07 ,pp. : 3134-3140

Elsevier

Access to resources Recommend Favorite

Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine

By Nolan T.   McIntyre P.   Roberton D.   Descamps D.  

Vaccine, Vol. 21, Iss. 3, 2002-12 ,pp. : 281-289

Elsevier

Access to resources Recommend Favorite

Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age

By Ceyhan M.   Kanra G.   Erdem G.   Kanra B.  

Vaccine, Vol. 19, Iss. 31, 2001-08 ,pp. : 4473-4478

Elsevier

Access to resources Recommend Favorite

Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection

By Cilla G.   Pena B.   Marimon J.M.   Perez-Trallero E.  

Vaccine, Vol. 14, Iss. 6, 1996-04 ,pp. : 492-494

Elsevier

Access to resources Recommend Favorite